ORMP - Oramed Pharma initiated buy at Cantor citing the potential of oral insulin therapy

Late March Oramed Pharmaceuticals ([[ORMP]] -1.2%) surged in reaction to the announcement of the beginning of the second of two simultaneous Phase 3 studies for its oral insulin capsule, ORMD-0801 that targets type 2 diabetes (T2D).Canaccord Genuity analyst Edward Nash has begun the coverage on the stock with a buy recommendation arguing, “Oramed has broken new clinical ground, with ORMD-0801,” which according to Nash is the first oral insulin to enter late-stage clinical trials.Large pharma and biotech have failed in the clinical development of oral insulin for T2D despite decades of efforts, the analyst wrote adding that ORMD-0801 has passed early-stage trials ‘with no serious adverse events.’With the company initiating the enrollment in two Phase 3 trials for ORMD-0801 in the previous quarter, Nash expects the top-line data from both trials in H1 2023 followed by a potential launch in H2 2024.However, according to the company’s latest 10-K report, one of the

For further details see:

Oramed Pharma initiated buy at Cantor citing the potential of oral insulin therapy